Related Experiment Video
Updated: Jun 9, 2025
10:27
In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
Published on: October 21, 2022
1.5K
Recent Progress of CircRNAs in Hematological Malignancies
Ya-Bin Cui1, Li-Jie Wang1, Jin-Hui Xu2
1Department of Hematology, Henan University People's Hospital and Henan Provincial People's Hospital, Zhengzhou 450003, P.R. China.
International Journal of Medical Sciences
|October 23, 2024
Summary
Circular RNAs (circRNAs) are crucial epigenetic regulators in blood cancers. This review highlights their role in disease progression and potential as biomarkers and therapeutic targets.
Area of Science:
- Molecular Biology
- Epigenetics
- Oncology
Background:
- Circular RNAs (circRNAs) are key epigenetic regulators involved in cellular activities like proliferation and apoptosis.
- Their stable structure makes them promising biomarkers for disease diagnosis and prognosis, especially in hematological malignancies.
Purpose of the Study:
- To review the role of circRNAs in the pathogenesis, progression, and therapeutic resistance of hematological malignancies.
- To explore the prognostic significance of circRNAs in predicting disease outcomes and treatment response.
Main Methods:
- Comprehensive literature review of studies on circRNAs in hematological malignancies.
- Analysis of circRNA involvement in cancer biology, diagnosis, prognosis, and therapy.
Main Results:
- CircRNAs play a significant role in the development and progression of hematological cancers.
- CircRNAs demonstrate potential as predictive biomarkers for patient outcomes and treatment efficacy.
- CircRNAs are implicated in therapeutic resistance in hematological malignancies.
Conclusions:
- Circular RNAs are pivotal in hematological malignancies, influencing pathogenesis and treatment response.
- CircRNAs offer a promising avenue for novel diagnostic and therapeutic strategies in blood cancers.
Related Concept Videos
01:21Hematopoiesis
5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K